Abstract：OBJECTIVE To prepare a ternary supersaturated indomethacin (IND) solid dispersion and investigate its characteristics by screening carrier materials with different functions based on quality by design (QbD) concept. METHODS Based on dissolution tests, the carriers with solubilization function were selected and the appropriate drug loading ratio of binary solid dispersion was determined. The material as inhibitor of precipitation was chosen using the solvent shift method. The IND ternary supersaturated solid dispersion was prepared by the hot melt extrusion of IND, solubilization material and precipitation inhibitor. The dispersion state of IND was identified by differential scanning calorimetry and powder X-ray diffraction, and its characteristics were explored by the powder wettability test and the stability test. RESULTS The binary IND solid dispersion with Eudragit EPO could sharply increase IND dissolution rate with a behavior of more than 80%dissolution within 5 min but subsequently followed an obvious concentration decline. Kollidon VA64 had a satisfactory effect of precipitation inhibition for IND supersaturated solution in that the concentration of 0.1% could keep the 50 μg·mL-1 IND solution unchanged within 30 min. The ternary solid dispersion with a mass ratio of 1∶2∶0.3 (IND∶EPO∶VA64) could significantly increase the dissolution of IND, eliminating the crystallization and precipitation of the drug in the supersaturated system during the dissolution process and enabling the drug to maintain amorphous form within 3 months. CONCLUSION Based on the understanding of the functions of different carrier materials and the QbD concept, it could effectively improve the formulation design of solid dispersions. The prepared ternary IND solid dispersions have excellent drug dissolution behavior.
李梦婷, 刘青, 张雅琦, 叶梦蝶, 王文喜. 基于QbD理念的吲哚美辛三元超饱和固体分散体系的制备及性能考察[J]. 中国药学杂志, 2020, 55(17): 1450-1455.
LI Meng-ting, LIU Qing, ZHANG Ya-qi, YE Meng-die, WANG Wen-xi. Preparation and Characterization of Ternary Indomethacin Solid Dispersion Based on Quality by Design (QbD) Concept. Chinese Pharmaceutical Journal, 2020, 55(17): 1450-1455.
YU L X. Pharmaceutical quality by design: product and process development, understanding, and control [J]. Pharm Res, 2008, 25(4):781-791.
[2]
CUI X S, CHEN Z Y, ZENG H X, et al. Development and validation of the production process of parecoxibsodium freeze-dried preparation based on quality by design [J]. Chin Pharm J(中国药学杂志), 2017, 52(15):1337-1341.
[3]
BROUWERS J, BREWSTER M E, AUGUSTIJNS P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? [J].J Pharm Sci, 2009, 98(8):2549-2572.
[4]
GROHGANZ H, PRIEMEL P A, LÖBMANN K, et al. Refining stability and dissolution rate of amorphous drug formulations[J]. Expert Opin Drug Deliv, 2014, 11(6):977-989.
[5]
VASCONCELOS T, MARQUES S, NEVES D J, et al. Amorphous solid dispersions: rational selection of a manufacturing process [J]. Adv Drug Deliv Rev, 2016, 100(1):85-101.
[6]
LAITINEN R, LÖBMANN K, GROHGANZ H, et al. Supersaturating drug delivery systems: the potential of co-amorphous drug formulations [J].Int J Pharm, 2017, 532(1):1-12.
[7]
LIU W L, WEI Z P. Recent progress on the solubility improvement for poorly water-soluble drugs by forming solid dispersions with novel carriers and advanced techniques [J].Chin Pharm J (中国药学杂志), 2016, 51(22):1901-1906.
[8]
ALONZO D E, ZHANG G G Z, ZHOU D, et al. Understanding the behavior of amorphous pharmaceutical systems during dissolution[J]. Pharm Res, 2010, 27(4):608-618.
[9]
YU L, SUN H, YANG R, et al. Development and application of functional excipients [J].Chin Pharm Aff (中国药事), 2013, 27(6):628-634.
[10]
RAINA S A, EERDENBRUGH B V, ALONZO D E, et al. Trends in the precipitation and crystallization behavior of supersaturated aqueous solutions of poorly water-soluble drugs assessed using synchrotron radiation [J]. J Pharm Sci, 2015, 104(6):1981-1992.
[11]
XIE T, GAO W, TAYLOR L S. Impact of Eudragit EPO and hydroxypropyl methylcellulose on drug release rate, supersaturation, precipitation outcome and redissolution rate of indomethacin amorphous solid dispersions [J]. Int J Pharm, 2017, 531(1):313-323.
[12]
SUN D D, LEE P I. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers [J]. J Controlled Release, 2015, 211:85-93.
[13]
LIU H, WANG P, ZHANG X, et al. Effects of extrusion process parameters on the dissolution behavior of indomethacin in Eudragit EPO solid dispersions [J]. Int J Pharm, 2010, 383(1-2):161-169.
[14]
SARODE A L, SANDHU H, SHAH N, et al. Hot melt extrusion (HME) for amorphous solid dispersions: predictive tools for processing and impact of drug-polymer interactions on supersaturation [J]. Eur J Pharm Sci, 2013, 48(3):371-384.
[15]
SIEPMANN J, SIEPMANN F. Mathematical modeling of drug dissolution [J]. Int J Pharm, 2013, 453(1):12-24.
[16]
PRASAD D, CHAUHAN H, ATEF E. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects [J]. J Pharm Sci, 2014, 103(11):3511-3523.
[17]
CHAMSAI B, SRIAMORNSAK P. Physical stabilizing effect of biopolymers on solid dispersions containing indomethacin and polyethylene glycol [J]. Adv Mater Res, 2012, 506:307-310.
[18]
SHI N Q, WANG S R, ZHANG Y, et al. Hot melt extrusion technology for improved dissolution, solubility and "spring-parachute" processes of amorphous self-micellizing solid dispersions containing BCS Ⅱ drugs indomethacin and fenofibrate: profiles and mechanisms [J]. Eur J Pharm Sci, 2019, 130:78-90.
2020, Vol. 55 
